"Adaptive pathways" to drug authorisation: adapting to industry?

BMJ. 2016 Aug 16:354:i4437. doi: 10.1136/bmj.i4437.

Authors

Courtney Davis¹, Joel Lexchin², Tom Jefferson³, Peter Gøtzsche⁴, Martin McKee⁵

Affiliations

¹ Department of Social Science, Health and Medicine, King's College London, London, UK courtney.davis@kcl.ac.uk.
² School of Health Policy and Management, York University, Toronto, Ontario, Canada.
³ Centre for Evidence Based Medicine, Oxford, UK.
⁴ Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
⁵ London School of Hygiene and Tropical Medicine, London, UK.

PMID: 27531201
DOI: 10.1136/bmj.i4437

No abstract available

MeSH terms

Drug Approval* / methods
Drug Industry*
Drug Therapy
Drug and Narcotic Control
Drug-Related Side Effects and Adverse Reactions
Europe
Humans
Risk Assessment
Time Factors